论文部分内容阅读
对３５例肺癌骨转移患者进行临床分析，结果发现肺癌骨转移病理学类型以腺癌为首，占４５．７％，转移部位以脊柱多见，占３８．７％，治疗方法上以化疗加用骨膦组止痛疗效高于单纯化疗组（Ｐ＜０．０５）。通过对肺癌骨转移临床分析，认为对肺癌患者进行全面检查可提高骨转移诊断率，化疗加骨膦治疗肺癌骨转移，可明显缓解疼痛，改善患者生活质量。
A clinical analysis of 35 patients with bone metastases from lung cancer found that the pathological type of bone metastases from lung cancer was led by adenocarcinoma, which accounted for 45.7%. The metastatic site was more common in the spine, accounting for 38.7%. The chemotherapy was used for chemotherapy. The efficacy of analgesia in bone phosphine group was higher than that in chemotherapy alone group (P<0.05). Through the clinical analysis of bone metastases of lung cancer, it is believed that conducting a comprehensive examination of lung cancer patients can increase the diagnostic rate of bone metastases. Chemotherapy plus bone phosphine for the treatment of lung cancer bone metastases can significantly relieve pain and improve the patient’s quality of life.